Health Economics and Multinational Randomised Controlled Trials
Collecting clinical efficacy and safety data in multinational randomised controlled trials (MNRCTs) has long been a means to achieve rapid recruitment of sufficient sample sizes in a timely manner. The strengths and weaknesses of this approach have been well explored in the literature. MNRCTs also provide an opportunity to collect health economic evidence, which introduces its own set of challenges. This editorial by Tamlyn Rautenberg of Assessment in Medicine AiM GmbH Research and Consulting & Peter Hall of St. James Institute of Oncology, University of Leeds provides an overview of special considerations when collecting health economic evidence alongside MNRCTs.